tumors from patients using a panel of immune system molecular markers, and assessed whether marker expression correlated with clinical outcomes. CD3, CD8 and PD-1 on tumor-infiltrating lymphocytes was significantly increased in secondary resected specimens compared with initially resected specimens (p ≤ 0.05). All patients expressed PD-L1 on tumor cells in initial and secondary resection specimens. Patients were divided into high or low expression group by median IHC score of PD-1 on initial or secondary resected specimens. No significant differences in patient outcomes were observed between high and low PD-1 or PD-L1 groups of initially resected specimens. In high expression group of secondary resected specimens, most patients score had increased which compared with initial resected tumor specimens. The PD-1 high expression score group of secondary resected specimens was associated with long progression-free survival and short survival after recurrence. PD-L1 expression was detected in almost all initial and secondary specimens. Patients with high PD-1 expression of secondary specimen had bad prognosis after secondary resection. PD-1/PD-L1 pathway may be associated with patient outcome after second surgery of glioblastoma.
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Abstract Glioblastoma (GBM) is the most common type of malignant brain tumor and has a very poor prognosis. Most patients relapse within 12 months despite aggressive treatment and patient outcome after recurrent is extremely worse. This study was designed to clarify the change of the molecular expression, including programmed cell death 1 (PD-1) and PD-ligand 1 (PD-L1), on the initial and secondary resected tumor specimens and to address the influence of these expressions for patient outcome after second surgery of glioblastoma. We investigated 16 patients, ranging in age from 14 to 65 years, with histologically verified WHO grade IV GBM, whose original tumor was resected between 2008 and 2014, and treated with fractionated radiotherapy and temozolomide. Four patients who were treated with immunotherapy using autologous formalin-fixed tumor vaccine were enrolled. All of the patients underwent secondary resection after tumor recurrence within 24 months. We carried out an immunohistochemical examination of the initial and secondary resected
Introduction
Glioblastoma (GBM) is the most common type of malignant brain tumor [1] [2] [3] . Despite aggressive treatment, including tumor resection, fractionated radiotherapy (FRT) and temozolomide (TMZ), the overall survival (OS) of patients with GBM is only 14.6 months [4] . Furthermore, patient outcomes after recurrence are generally dismal, with a median OS of less than 10.8 months [5] [6] [7] [8] . Various studies have shown that anti-angiogenic antibodies or intraoperative chemotherapeutic implantation do not dramatically improve patient outcomes [9, 10] .
Although isocitrate dehydrogenase-1 (IDH-1) mutation, O 6 -methylguanine-methyltransferase (MGMT) methylation status and Ki-67 index for initially diagnosed GBM are predictive biomarkers associated with suitability for additional treatment or prognosis, there are few biomarkers that are useful after recurrence [8, 11] . Previous studies showed that expression of TP53, MDM2, MSH2 and EGFRvIII was down-regulated in recurrent GBM [12, 13] . In other types of recurrent malignant tumors, including breast cancer and colorectal cancer, patient outcomes were influenced by the tumor immune microenvironment [14, 15] .
We have performed immunotherapy using autologous formalin-fixed tumor vaccine (AFTV) for initially diagnosed GBM [16] [17] [18] [19] . In these studies, we found that a part of patients treated with AFTV had very good prognosis, while some patients had unfavorable outcomes. However, any molecular marker relating to patient prognosis was not determined.
More recently, immune checkpoint inhibitors are attracting attention as a new treatment strategy that helps immune cells recognize and attack cancer cells [20, 21] . In patients with malignant melanoma and non-small cell lung cancer, which carry a relatively high number of somatic mutations, treatment with an anti-PD-1 antibody induced a significant and durable reduction in tumor volume [20, 21] . A high number of somatic mutations is thought to be a predictive marker of effectiveness for checkpoint inhibitor immunotherapy, because the degree of mutation represents the height of antigenicity and to be considered induction of cytotoxic T cell lymphocyte (CTL) repertoire [22] . Although there have been a few studies addressing the associations between PD-1/PD-1 ligand (PD-L1) expression in GBM and patient outcomes [23] [24] [25] , the value of PD-1/PD-L1 expression as a prognostic marker remains controversial. We studied the immune system molecular markers by immunohistochemical examination of initially and secondary resected tissues from patients with GBM treated with FRT and TMZ at our institution, and assessed whether marker expression correlated with clinical outcomes after second surgery.
Materials and methods
Patients and GBM specimens
We retrospectively investigated 16 patients with histologically verified WHO grade IV GBM, ranging in age from 14 to 65 years, who received the first surgical tumor removal between 2008 and 2014, and treated with FRT and TMZ at our institute (Department of Neurosurgery, Faculty of Medicine, University of Tsukuba). All patients, including four patients who were treated with AFTV, and other four patients who were treated with proton therapy, underwent secondary resection after tumor recurrence within 24 months. The study included three patients registered in the University Hospital Medical Information Network (UMIN) clinical trials number 000001426, the study design and treatment protocol of which were approved by the ethics committees of our institute [17] , and a patient treated with AFTV who was reported in a previous paper [19] . The AFTV was prepared from autologous formalin-fixed tumor tissue and administered with adjuvant microparticles as described previously [16, 18] .
Pathological examination
Histopathological diagnosis was confirmed according to the 2007 WHO criteria [26] by pathologists at Tsukuba University Hospital or the Japan Brain Tumor Reference Center at Gunma University (Maebashi, Japan) using paraffin-embedded tissue sections stained with hematoxylin and eosin (H&E). Formalin-fixed paraffin embedded (FFPE) sections (2 µm) were deparaffinized in xylene and rehydrated through graded alcohols (99.5-70%). Antigen retrieval was carried out using target retrieval solution (pH 6.0; Dako) for PD-L1 or citric acid buffer (pH 6.0) for other molecules for 10 min in a microwave (specimens were put in a microwavable pressure cooker when using microwave). Endogenous peroxidase activity was quenched by immersion in 0.3% hydrogen peroxide in methanol for 30 min at room temperature and the sections were then incubated with primary antibodies at 4 °C overnight. The next day, the slides were incubated with a secondary biotinylated antibody (LSAB2 Kit; Dako) at room temperature for 10 min. After another 10 min incubation with streptavidin-horse radish peroxidase (LSAB2 kit; Dako), reactions were developed using a Liquid DAB Substrate Chromogen system (Dako). The slides were counterstained with 50% Mayer's hematoxylin and dehydrated through graded alcohols (80-99.5%) and xylene, then cover slipped with EUKITT (mounting reagent).
Monoclonal antibodies used for immunohistochemistry (IHC) included anti-Ki-67 (MIB-1, Dako), anti-TP53 (DO-7, Dako), anti-MHC class I (W6/32, Santa Cruz Biotechnology), anti-MHC class II (LN3, Novus), anti-IDH-1R132H (D299-3, MBL), anti-CD3 (SP7, Novus), anti-CD8 (SP16, Gene Tex), anti-CD20 (BV11, Novus), anti-CD45RO (UCH-L1, Santa Cruz Biotechnology) and anti-PD-L1 (28-8, Abcam). Polyclonal antibodies included anti-Granzyme B (GRZB) (E2582, Spring Bioscience), anti-PD-1 (E18662, Spring Bioscience) and anti-ATRX (HPA001906, Sigma Aldrich).
Staining indices were calculated as the average number of positive cells in randomly chosen pairs of vascular rich and relatively hypo-vascular areas with appropriate staining condition from the entire section, with a total number of cells not less than 1000. The Ki-67 and TP53 indices were expressed as percentages. For category analysis, cases with 10% or more positive cells were deemed positive, and cases with fewer than 10% positive cells were deemed negative for TP53 [27] . For IDH1-R132H and ATRX, cases with 50% or more positive cells were rated as positive, and cases with fewer than 50% positive cells were rated as negative. Expression of CD3, CD8, CD20, CD45RO, GRZB and PD-1 in infiltrating immune cells was scored as 1 point (0 to 4 cells per high power field, x400), 2 points (5-8 cells), 3 points (9-12 cells) and 4 points (13 cells or more). Staining scores, which were the sum (2-8 points) of two median values of each of three points in the vascular-rich areas (1-4 points) and the relatively hypo-vascular areas (1-4 points) were used for analysis, modifying a method described previously [15] . Expression of MHC class I and PD-L1 in tumor cells was graded as '−' (absence of staining), '+' (up to 25% of cells stained), '++' (25-50% of cells stained) or '+++' (more than 50% of cells stained) [27, 28] . The IHC evaluation was performed by one of the authors (T. M.) with no reference to other clinical data.
DNA extraction and bisulfite treatment
Genomic DNA was extracted from freshly frozen tissue using a DNeasy ® Blood and Tissue Kit (Qiagen) according to manufacturer's instructions. Genomic DNA (1 μg) was bisulfite modified by the MethylEasy ™ Xceed Rapid DNA Bisulphite Modification Kit (Human Genetic Signatures), following the manufacturer's protocol. Modified DNA was purified and used immediately. Bisulfite modified genomic DNAs from Hela and U87 cell lines were used as positive controls for unmethylated and methylated DNA, respectively. Distilled water was used as negative control.
Methylation specific PCR (MSPs)
MSPs were carried out with 50 ng of bisulfite modified DNA in a total volume of 10 μl, which contained 5 μl of 2x AmpliTaq Gold ™ Fast PCR Master Mix (Applied Biosystems), in a Veriti thermocycler (Applied Biosystems). Oligonucleotide primers for methylated or unmethylated MGMT were described previously [29] . PCR reactions were 95 °C for 10 min, followed by 40 cycles of 30 s denaturation at 96 °C, 30 s annealing at 62 °C, 30 s extension at 68 °C and a final extension step at 72 °C for 30 s. PCR products were electrophoresed in a 2% agarose gel and stained with ethidium bromide at a final concentration of 0.1 μg/ml.
Statistical analysis
All results are presented as absolute number (%) or median (range). Statistical analyses were performed using standard statistical software (IBM SPSS Statistics version 24.0 for Windows; SPSS, Chicago, IL, USA). For comparison of IHC score and grade, Wilcoxon tests between initial and secondary specimens and Mann-Whitney U tests between initial specimens of vaccine group and control group were used, respectively. OS from diagnosis to death or last follow-up was estimated using the Kaplan-Meier limit method. The log-rank test was used to assess group differences. P values of <0.05 were considered statistically significant.
Results
The characteristics, IHC pathological status at the first surgery, and treatment histories after surgery of the 16 patients are presented in Table 1 . Two patients had IDH-1 mutation and diagnosed with secondary GBM. Figure 1 shows micrographs of CD8 and PD-1 membranous expression on tumor-infiltrating lymphocytes (TILs) in initially resected and secondary resected specimens from a representative recurrent case after AFTV treatment. Although double-staining could not be done due to the host type of antibody used in this study, most (approximately 74%) of CD8+ T cells co-expressed PD-1 in evaluable TILs using consecutive tissue sections. Remaining CD8+ T cells were PD-1 negative cells. High and low PD-L1 membranous expression on tumor cells, and PD-1 expression on TILs of representative cases are shown in Fig. 2 . Table 2 shows IHC indices, staining scores and grades (see "Material and methods" section) of TILs and tumor cells for specimens obtained from first and second surgeries. Ki-67, P53, ATRX, IDH1R132H, HLA-ABC, HLA-DR and PD-L1 staining scores or indices were not significantly different. CD3, CD8 and PD-1 staining scores were significantly increased in secondary resected specimens compared with initially resected specimens (p ≤ 0.05), and CD20, CD45RO and GRZB staining scores were unaltered.
Patients were divided into high (7 or more) or low PD-1 score group (less than 7) by PD-1 staining scores on secondary specimens. PD-1 (as an activated/exhausted lymphocyte marker) expression scores of the high PD-1 score group was significantly increased in secondary resection specimens compared with initial resection specimens (p ≤ 0.05) (Fig. 3a) . All patients treated with AFTV increased PD-1 score on secondary specimens compared with initial specimens. CD3 (T cell receptor), CD8 (cytotoxic lymphocyte marker) and CD45RO (memory T cell marker) expression scores were also significantly increased in high PD-1 score group (data not shown). There was no significant differences in molecular marker expression on TILs between the initial and secondary specimens of low PD-1 score group. No significant difference was seen between high and low PD-1 score groups on the initial specimens.
To assess the association between marker expression and patient outcomes, univariate analyses of PFS, survival from secondary surgery and OS (from initial surgery) in high-and low-expression groups were performed. Figure 3b shows the survival curves of the high and low PD-1 score groups on secondary specimens. In log-rank analysis, high PD-1 score after the secondary surgery was a significant factor associated with favorable PFS, and low PD-1 score after the secondary surgery was also significant for improved survival. PD-1 score and other molecular score including Ki67 score and P53 score did not correlate in this study. High CD8 score after the secondary surgery was also significant poor prognostic factor of survival after second resection as high PD-1 score (p = 0.005), and high CD3 score was trend of poor prognostic factor of survival after second resection (p = 0.065). In tumor markers, high PD-L1 grading also show trend of favorable prognostic factor of PFS (p = 0.095). Univariate log-rank analysis of other IHC data, including ATRX, IDH-1R132H and others, revealed that positive ATRX staining after the initial surgery was the only significant factor (p < 0.05) associated with favorable PFS. No significant differences were observed for other factors, including IDH-1R132H staining status, probably due to low patient numbers.
Discussion
The balance of cytotoxic CD8+ TILs and negative immune regulators, such as PD-1/PD-L1 expression and regulatory T cells in the tumor microenvironment, are critical determinants of patient outcome associated with both the intrinsic and immunotherapy mediated immune response [30] . In this study, the IHC expression scores of CD3, CD8
and PD-1 on TILs were significantly increased in the secondary resection specimens compared with the initial resection specimens, although CD20 and GRZB scores were not Fig. 3 a Scatter plot depicting the expression scores of PD-1 on TILs in initial and secondary resected specimens. High and low PD-1 expression on secondary resection specimens grouped as higher or lower than median IHC score [low PD-1 score group (less than 7), n = 7; High PD-1 score group (7 or more), n = 9]. White circles show 4 patients treated with AFTV. For comparisons of IHC score, the Wilcoxon test between initial and secondary specimens and MannWhitney U test between initial specimens of the low group versus high group were used, respectively. p < 0.05 were considered statistically significant. b Kaplan-Meier curves showing PFS, survival after secondary resection and OS compared with high and low PD-1 expression on secondary resection specimens grouped as higher or lower than median IHC score [blue line low PD-1 score group (less than 7), n = 7; green line high PD-1 score group (7 or more), n = 9]. These curves compared with high and low CD8 and PD-L1 expression on secondary resection specimens are also shown different. These results indicated that various stimulations including AFTV treatment induce the recruitment of large numbers of T cell type TILs, consisting mostly of CD8+ cytotoxic T cells. However, most of the CD8+ TILs coexpressed PD-1. PD-1 positive TILs including these CD8 T cells were in the exhausted state at the recurrent stage. Earlier research revealed that inflammatory cytokines, such as interferon alfa (IFNα) and interferon gamma (IFNγ) secreted by activated T cells, mediate PD-1 expression on TILs and PD-L1 expression on tumor cells, respectively. This mechanism is considered to be an important factor associated with tumor recurrence [31, 32] . In this study, PD-L1 expression on tumor cells was detected in all specimens, and the secretion of inflammatory cytokines accumulated TILs may be linked to this phenomenon. In addition, GRZB downregulation was observed in PD-1 expressing TILs as shown in Fig. 1 . We speculate that activated TILs were attenuated by inhibitory factors, such as accumulating regulatory T cells or myeloid derived suppressor cells, PD-1/PD-L1, inhibitory factors (TGF-beta, IL-10, IDO) or tryptophan catabolites, all of which are found in various tumor microenvironments [33, 34] .
The results of our previous Phase IIa clinical study of FRT, TMZ and AFTV immunotherapy for initially diagnosed GBM patients included a 33% 2-year progressionfree ratio, 22.2 months OS and 38% 3-year survival ratio [17] . In other words, a third of patients had a long PFS of over 24 months resulting in an extremely favorable outcome, and half of the rest of the patients had an unfavorable outcome. Thus, it will be very valuable to identify the mechanisms underlying early AFTV treatment failure. In the present study, all of the tumors in the AFTV group recurred within 24 months, and there were no patients with a PFS over 24 months. In our experience, most patients with a PFS over 24 months do not have a recurrence within the follow-up period of 3.1 years. Instead, typically they may have a small mass in a new location distal from the original lesion that is treatable with stereotactic radiotherapy. For this reason, the present study includes only AFTV failure patients with a relatively short PFS.
Our data showed that cases with increased numbers of PD-1 positive TILs at the secondary surgery tended to have a favorable PFS. We speculate that PFS was extended by spontaneously or AFTV induced PD-1 negative CD8 TILs that attack the remaining tumor cells after the initial surgery and inhibit tumor progression. On the other hand, TILs had a limited capacity to infiltrate tumor tissue and influence tumor growth. However, the PD-1 low group had better survival after secondary surgery compared with the high group. We speculate that expansion of PD-1 negative CD8 T cells probably extend the interval to recurrence. After TILs including CD8 T cells beginning to express PD-1, tumor may recur rapidly. Almost all TILs express PD-1 after secondary surgery in the high groups, and there were minimal numbers of active TILs that were able to influence tumor progression consistent with very poor prognosis. Median survival from secondary surgery for the PD-1 high group and PD-1 low group was 13.8 and 18.4 months, respectively.
There are few studies addressing the association between PD-1/PD-L1 expression in GBM and patient outcomes. Nduom et al. examined 92 GBMs by IHC and reported that high expression of PD-L1 on GBM cells was a poor prognostic marker [25] . In contrast, Berghoff and coauthors examined 117 initially diagnosed and 18 recurrent GBMs by IHC and did not find a correlation between high PD-L1 expression and prognosis [23] . In regard to other mechanisms that may be related to AFTV treatment failure, we speculate that some hyper-proliferative tumors will recur until acquired immunity is established after AFTV administration.
Our results indicate that anti-PD-1 antibody therapy may effective for preventing tumor recurrence after initial surgery. In a mouse breast cancer model (TUBO cell xenograft), combination therapy with a multi-peptide vaccine and anti-PD-1 antibody prolonged survival of tumor-bearing mice and enhanced TIL antigen reactivity [35] . Further, in colon cancer (CT26 cell xenograft) and ovarian cancer (ID8-VEGF cell xenograft) mouse models, the combination therapy of vaccination or adaptive transfer of TILs and double immune checkpoint blockade (CTLA-4 and PD-1) blocked tumor growth more effectively than monotherapy or combination therapy with single immune checkpoint blockade [36] . Anti-CTLA-4 antibody inhibits the negative regulation by CTLA-4 signaling in the activation phase of the APC-T cell interaction, and enhances anti-tumor effects as a result of T cell activation and proliferation [37] . However, it has been reported that the side effects of double immune checkpoint blockade combination therapy are significant [38] . In our cohort, AFTV induced high numbers of TILs with no or very weak side effects (e.g. redness and/or induration in the administration skin site, and mild fever). In addition, combination therapy with AFTV, pembrolizumab (anti-PD-1 antibody) and radiation was effective for the treatment of chemo-refractory liver-metastasized uterine cervical small cell carcinoma [39] . Thus, we expect that combination therapy with AFTV and anti-PD-1 antibody is a more effective and safer method for cancer immunotherapy.
Our study has some limitations. The characteristics of our patient group were not typical for standard GBM patients because only recurrent cases treated with repeated surgery were included. The past study did not show a correlation between PD-L1 expression and MGMT methylation status in 117 newly diagnosed GBMs [23] . Another previous analysis of 222 GBMs also found no relationship between MGMT methylation status, TP53 expression, or enhancement of PD-1 positive TILs or PD-L1 expression on tumor cells at the tumor site [40] . So we speculate that bias based on MGMT methylation status and TP53 expression might not be related to the presence of PD-1-positive TILs. We could not prove that PD-1 positive TILs were reduced in long PFS (over 24 months) patients treated with AFTV, or patients with no tumor recurrence who had a coincidental second operation, because it is very difficult to obtain TILs from these patients. We speculate that recurrence is not observed in long PFS patients because tumor cells have already been eliminated even if some PD-1 positive TILs are induced. Moreover, GBM heterogeneity might make it difficult to evaluate with precision whether high PD-1/PD-L1 expression after secondary surgery shortens OS, and the small number of patients is also a limitation of this study, and further analysis using a larger number of patients is necessary.
Conclusion
PD-L1 expression was detected in almost all initial and secondary specimens. In the vaccinated group, the expression of PD-1 on TILs was significantly upregulated in secondary resected specimens compared with the initially resected tumors (p ≤ 0.05). The patients with high PD-1 expression in the secondary specimens had long PFS, and short survival after recurrence. PD-1/PD-L1 pathway may be associated with patient outcome after second surgery of glioblastoma.
